References
1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493–537.
2. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43–54.
3. Yoon HJ, Jin SW, Jung SJ, Jang SH, Lee JM, Kim JH, et al. A case of hyperthyroidism as a cause of pulmonary hypertension. Korean J Med 2003;65:S773–6.
4. Choi BH, Eom YS, Kim SH, Choi HS, Chung WJ, Lee SH. A case of ascites and extensive abdominal distension caused by reversible pulmonary arterial hypertension associated with Graves'disease. Endocrinol Metab 2011;26:248–52.
5. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501–9.
6. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002;122:1668–73.
7. Suk JH, Cho KI, Lee SH, Lee HG, Kim SM, Kim TI, et al. Prevalence of echocardiographic criteria for the diagnosis of pulmonary hypertension in patients with Graves' disease: before and after antithyroid treatment. J Endocrinol Invest 2011;34:e229–34.
8. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuricemia in severe pulmonary hypertension. Chest 2000;117:19–24.
9. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865–70.
10. Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525–9.